Serology in COVID-19: Comparison of Two Methods

Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbot...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of environmental research and public health Vol. 18; no. 12; p. 6497
Main Authors Moniuszko-Malinowska, Anna, Jelski, Wojciech, Dunaj, Justyna, Mroczko, Barbara, Czupryna, Piotr, Kruszewska, Ewelina, Pancewicz, Sławomir
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 16.06.2021
MDPI
Subjects
Antigens
Brief Report
Coronaviruses
COVID-19
Disease transmission
Immunoassay
Immunoglobulin G
Infections
Infectious diseases
Medical personnel
Medical research
Monoclonal antibodies
Plasma
Proteins
Serological tests
Serology
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Spike protein
Statistical analysis
Viruses
Poland
Online AccessGet full text

Cover

More Information
Summary:Background: The aim of our study was to examine the performance of two assays in detecting SARS-CoV-2 antibodies. Methods: A total of 127 COVID-19 disease contacts from the Infectious Diseases Department were included. Two serological tests were used: SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) and LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin). Results: The assays exhibited a 96.85% (123/127 patients) test result agreement. In two cases, the positive results obtained by SARS-CoV-2 IgG CMIA on the Alinity system (Abbott) were negative based on the LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test, and in two cases, negative results from the LIAISON® SARS-CoV-2 S1/S2 IgG CLIA (DiaSorin) test were positive with the SARS-CoV-2 IgG CMIA on the Alinity system (Abbott). Conclusions: Based on the results of our study, we conclude that in population medicine, the assessments of anti-SARS-CoV-2 antibodies after exposure to SARS-CoV-2 virus based on spike protein or nucleocapsid protein show comparable effectiveness.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 754432 and the Polish Ministry of Science and Higher Education, from financial resources for science in 2018–2023 granted for the implementation of an international co-financed project.
ISSN:1660-4601
1661-7827
1660-4601
DOI:10.3390/ijerph18126497